Cargando…

Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination

There is an urgent need to develop new innovative therapies for the control of cancer. Antigen-specific immunotherapy and the employment of proteasome inhibitors have emerged as two potentially plausible approaches for the control of cancer. In the current study, we explored the combination of the D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Chih-Wen, Monie, Archana, Wu, Chao-Yi, Huang, Bruce, Wang, Mei-Cheng, Hung, Chien-Fu, Wu, T.-C.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2008
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2535907/ https://www.ncbi.nlm.nih.gov/pubmed/18542898 http://dx.doi.org/10.1007/s00109-008-0370-y

Ejemplares similares

Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
por: Chuang, Chi-Mu, et al.
Publicado: (2010)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects
por: Chuang, Chi-Mu, et al.
Publicado: (2009)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
por: Wu, Chao-Yi, et al.
Publicado: (2010)

Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8(+) T cell immune response and antitumor effects in a preclinical cervical cancer model
por: Huang, Zhuomin, et al.
Publicado: (2015)

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib
por: Neznanov, Nickolay, et al.
Publicado: (2011)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity
por: Tseng, Ssu-Hsueh, et al.
Publicado: (2022)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Delivery of Antigen to CD8(+) Dendritic Cells by Fusing Antigen With Formyl Peptide Receptor-Like 1 Inhibitor Protein Induces Antitumor Immunity
por: Chiang, Chen-Yi, et al.
Publicado: (2019)

ATRT-01. UPREGULATION OF PROTEIN SYNTHESIS AND PROTEASOME DEGRADATION CONFERS SENSITIVITY TO PROTEASOME INHIBITOR BORTEZOMIB IN MYC-ATYPICAL TERATOID/RHABDOID TUMORS
por: Tran, Minh-Huy, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8(+)T cell antitumor function
por: Pellom, Samuel T., et al.
Publicado: (2016)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination
por: Mao, Chih-Ping, et al.
Publicado: (2011)

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B
por: Reynolds, Jennifer M, et al.
Publicado: (2007)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
por: Sridhar, Settu, et al.
Publicado: (2013)

The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina
por: Chen, Fang-Ting, et al.
Publicado: (2013)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
por: Taromi, Sanaz, et al.
Publicado: (2017)

In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib
por: Bunea, Mihaela-Cristina, et al.
Publicado: (2023)

Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2014)

Control of Tumors by Antigen-Specific CD8(+) T Cells through PDL1-Targeted Delivery of Antigenic Peptide
por: Feng, Po-Hao, et al.
Publicado: (2022)

Bortezomib, a Proteasome Inhibitor, Attenuates Angiotensin II-Induced Hypertension and Aortic Remodeling in Rats
por: Li, Shuai, et al.
Publicado: (2013)

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_931r89mieg5otl29mfm4a9nsnm